Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoY
Resolved · earnings · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-13. Check what remains unresolved below before relying on it.
Does the new outlook change what the company is worth?
Immunology revenue growth to $2.6 billion diversifies Eli Lilly's top-line cash flows away from core incretin franchise concentration.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factEli Lilly's Immunology unit generated $2.6 billion in revenue in H1 2026, up 9% year-over-year. |
| What else was confirmed? | Reported factImmunology represented 6.1% of Eli Lilly's total top-line revenues during the period. |
| Does the valuation support acting? | Interpretation5 stored valuation assumptions for LLY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownImmunology Segment Run-Rate — Quarterly prescription volume trajectories for Ebglyss and Omvoh. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Eli Lilly's Immunology unit generated $2.6 billion in revenue in H1 2026, up 9% year-over-year.
- · Immunology represented 6.1% of Eli Lilly's total top-line revenues during the period.
- · Growth was led by Taltz alongside newer launches Ebglyss and Omvoh, supported by the integration of DICE, Morphic, and Merida.
Public research record
Research framework · page evidenceCompleted event assessment
non-incretin revenue diversification supporting gross margin stability
| Type | Claim | Scope |
|---|---|---|
| Assumption | Eli Lilly's Immunology unit generated $2.6 billion in revenue in H1 2026, up 9% year-over-year. | 2026-09-13 |
| Interpretation | non-incretin revenue diversification supporting gross margin stability | LLY |
Countercase, invalidators, and sources
Ebglyss and Omvoh uptake accelerates above 15% YoY, lifting Immunology above 8% of total Lilly sales.
- · Immunology Segment Run-Rate — Quarterly prescription volume trajectories for Ebglyss and Omvoh.
- Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s · 2026-09-11
What remains unresolved
- Base path
- Immunology delivers high single-digit growth near $5.3B annualized run-rate.
- Adverse path
- Pricing pressure in core biologics slows unit growth below 5% YoY.
- Supportive path
- Ebglyss and Omvoh uptake accelerates above 15% YoY, lifting Immunology above 8% of total Lilly sales.
- · Immunology Segment Run-Rate — Quarterly prescription volume trajectories for Ebglyss and Omvoh.this week
Evidence
- Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s2026-09-11
“Eli Lilly's Immunology division generated $2.6 billion in revenues in H1 2026, up 9% year-over-year, representing 6.1% of total revenues.”
Supports: Eli Lilly's Immunology division generated $2.6 billion in revenues in H1 2026, up 9% year-over-year.